Filing Flows › Comparisons › GENB vs VRCA
Generate Biomedicines vs Verrica Pharmaceuticals: GENB and VRCA compared
Generate Biomedicines is the larger company: $6.3M of revenue in its latest quarter (Q2 2026) against $5.9M for Verrica Pharmaceuticals (Q2 2026). Generate Biomedicines is growing faster (-38% against -54% a year earlier).
Where the money goes: GENB and VRCA
Generate Biomedicines (GENB) · Q2 2026
Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year), net loss $67.3M, operating cash flow −$57.9M. The chart follows the revenue to costs, profit and cash.
Verrica Pharmaceuticals (VRCA) · Q2 2026
Verrica Pharmaceuticals, Q2 2026: revenue $5.9M (-54% year over year), operating margin -223.4%, net loss $13.2M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
| Generate Biomedicines (GENB) | Verrica Pharmaceuticals (VRCA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $6.3M | $5.9M |
| Revenue growth, Y/Y | -38% | -54% |
| Operating margin | n/m | -223.4% |
| Net earnings | −$67.3M | −$13.2M |
| Net margin | — | -224.4% |
| Operating cash flow | −$57.9M | −$9.3M |
Questions
Which is bigger, Generate Biomedicines or Verrica Pharmaceuticals?
Generate Biomedicines is the larger company: $6.3M of revenue in its latest quarter (Q2 2026) against $5.9M for Verrica Pharmaceuticals (Q2 2026).
Is Generate Biomedicines or Verrica Pharmaceuticals growing faster?
Generate Biomedicines is growing faster (-38% against -54% a year earlier).
More: Generate Biomedicines earnings · how Generate Biomedicines makes money · Verrica Pharmaceuticals earnings · how Verrica Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.